| scholarly article | Q13442814 |
| P2093 | author name string | Zobair Younossi | |
| P2860 | cites work | Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients? | Q26801828 |
| The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C | Q27009292 | ||
| Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens | Q28081966 | ||
| The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry | Q30689293 | ||
| Ethics in practice: managed care and the changing health care environment: medicine as a profession managed care ethics working group statement | Q33204949 | ||
| American College of Physicians Ethics Manual: sixth edition. | Q34244075 | ||
| Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States | Q35619161 | ||
| Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes | Q37223591 | ||
| The impact of hepatitis C burden: an evidence-based approach. | Q38181631 | ||
| The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus | Q41207230 | ||
| Cost-effectiveness of novel regimens for the treatment of hepatitis C virus | Q41211125 | ||
| Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States | Q41366537 | ||
| Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease | Q41486392 | ||
| Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection | Q41522918 | ||
| Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir | Q42153423 | ||
| Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials | Q42173527 | ||
| Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study | Q42226115 | ||
| Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens | Q42226250 | ||
| Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. | Q42250432 | ||
| Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients | Q42253588 | ||
| An ethical template for pharmacy benefits | Q44278839 | ||
| An ethical framework for pharmacy management: balancing autonomy and other principles | Q58662883 | ||
| P433 | issue | 5 | |
| P921 | main subject | hepatitis C | Q154869 |
| medical ethics | Q237151 | ||
| P304 | page(s) | 117-119 | |
| P577 | publication date | 2015-11-01 | |
| P1433 | published in | Clinical liver disease | Q27726171 |
| P1476 | title | What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection? | |
| P478 | volume | 6 |
| Q90694549 | Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West |
| Q46566732 | Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis. |
| Q90709883 | Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition |
| Q41918142 | The Efficacy of New Anti-Viral Regimens for Hepatitis C Infection: Evidence from A Systematic Review |
Search more.